Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Norfloxacin

FDA-approved product (tablet, oral), marketed as Chibroxin, Noroxin.

Registered studies
30
Lab records
179
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Norfloxacin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Eye infection

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Fluoroquinolones
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01MA06; WHO ATC S01AE02

Repurposing investigation

Norfloxacin is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA93.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli98.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae92.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis74.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

30registered studies name this medicine, for any condition. See them below.

Experimental

  • MRSA: measured active in 45 of 47 lab records
  • E. coli: measured active in 51 of 52 lab records
  • K. pneumoniae: measured active in 65 of 80 lab records
Open Norfloxacin in ChEMBL Registered studies below
Show the latest 150 of 179 laboratory records, with sources

Loading records…

Every record is in ChEMBL, linked above. “Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Norfloxacin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Comparative Study of Rifaximin Versus Norfloxacin in the Secondary Prophylaxis of Spontaneous Bacterial Peritonitis

    NCT02120196 · start 2014-01

    Registered record
    Registry ID
    NCT02120196
    Conditions
    Spontaneous Bacterial Peritonitis; Ascites; Liver Cirrhosis
    Interventions
    Rifaximin; Norfloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2014-01
    Completion
    2023-12
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSpontaneous Bacterial Peritonitis; Ascites; Liver Cirrhosis
    InterventionRifaximin; Norfloxacin
    PhasePhase 3
    Registry statusUnknown

  • Comparison in the Treatment of Acute Cystitis Using Cephalosporin and Norfloxacin (CECI)

    NCT01527019 · start 2012-10

    Registered record
    Registry ID
    NCT01527019
    Conditions
    Cystitis
    Interventions
    Norfloxacin; Cephalosporins; Cephalosporins
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2012-10
    Completion
    Not recorded
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystitis
    InterventionNorfloxacin; Cephalosporins; Cephalosporins
    PhasePhase 3
    Registry statusWithdrawn

  • Symptomatic Therapy of Uncomplicated Lower Urinary Tract Infections in the Ambulatory Setting.

    NCT01039545 · start 2012-02

    Registered record
    Registry ID
    NCT01039545
    Conditions
    Urinary Tract Infections
    Interventions
    Diclofenac; Norfloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2012-02
    Completion
    2015-01
    Enrolment
    253

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Tract Infections
    InterventionDiclofenac; Norfloxacin
    PhasePhase 4
    Registry statusTerminated

  • Norfloxacin Versus Ciprofloxacin for Spontaneous Bacterial Peritonitis (SBP) Prevention

    NCT01542801 · start 2011-08

    Registered record
    Registry ID
    NCT01542801
    Conditions
    Adverse Reaction to Other Drugs and Medicines
    Interventions
    Norfloxacin; ciprofloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-08
    Completion
    2016-04
    Enrolment
    124

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdverse Reaction to Other Drugs and Medicines
    InterventionNorfloxacin; ciprofloxacin
    PhasePhase 4
    Registry statusCompleted

  • Norfloxacin Therapy for Patients With Cirrhosis and Severe Liver Failure

    NCT01037959 · start 2010-04

    Registered record
    Registry ID
    NCT01037959
    Conditions
    Cirrhosis
    Interventions
    Norfloxacin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2010-04
    Completion
    2015-11
    Enrolment
    291

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCirrhosis
    InterventionNorfloxacin; Placebo
    PhasePhase 3
    Registry statusTerminated

  • Enterobacteriaceae Producing Extended-spectrum β-lactamases (ESBL) Decolonization Study

    NCT00826670 · start 2009-06

    Registered record
    Registry ID
    NCT00826670
    Conditions
    Enterobacteriaceae Infections
    Interventions
    Decolonization; Placebo (Decolonization)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-06
    Completion
    2012-08
    Enrolment
    58

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEnterobacteriaceae Infections
    InterventionDecolonization; Placebo (Decolonization)
    PhasePhase 4
    Registry statusCompleted

  • Role of Probiotics in the Prevention of Spontaneous Bacterial Peritonitis in Cirrhotic Patients: A Randomized Placebo Control Trial

    NCT00678613 · start 2007-07

    Registered record
    Registry ID
    NCT00678613
    Conditions
    Spontaneous Bacterial Peritonitis; Liver Cirrhosis
    Interventions
    Probiotics and Placebo; Probiotics and Norfloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2007-07
    Completion
    Not recorded
    Enrolment
    250

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSpontaneous Bacterial Peritonitis; Liver Cirrhosis
    InterventionProbiotics and Placebo; Probiotics and Norfloxacin
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • A Pilot Study of Norfloxacin for Hepatopulmonary Syndrome

    NCT00362752 · start 2006-10

    Registered record
    Registry ID
    NCT00362752
    Conditions
    Hepatopulmonary Syndrome
    Interventions
    Norfloxacin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2006-10
    Completion
    2009-12
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatopulmonary Syndrome
    InterventionNorfloxacin; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Evaluation of Safety & Efficacy of Synbiotic on the Incidence and Recurrence of Spontaneous Bacterial Peritonitis (SBP) in Cirrhotics

    NCT00947336 · start 2005-04

    Registered record
    Registry ID
    NCT00947336
    Conditions
    Cirrhosis With Ascites
    Interventions
    Norfloxacin + Synbiotic; Norfloxacin + Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-04
    Completion
    2008-04
    Enrolment
    110

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCirrhosis With Ascites
    InterventionNorfloxacin + Synbiotic; Norfloxacin + Placebo
    PhasePhase 3
    Registry statusCompleted

  • Mortality Control Program for Economically Productive Age Group in Tribal Area of Melghat.

    NCT07436104 · start 2004-01-01

    Registered record
    Registry ID
    NCT07436104
    Conditions
    Hypertension (HTN); Diarrhea; Pneumonia; Malaria Fever; COPD; Asthma (Diagnosis); Diarrhea Chronic
    Interventions
    Trained village health workers (VHWs) , provided treatment of HTN, diarrhoea, malaria, pneumonia, asthma and COPD by Amlodipine, ORS, Norfloxacin, Chloroquine, Azithromycin, salbutamol rotacaps; Appropriate referral
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2004-01-01
    Completion
    2023-08-31
    Enrolment
    72,564

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension (HTN); Diarrhea; Pneumonia; Malaria Fever +3 more
    InterventionTrained village health workers (VHWs) , provided treatment of HTN, diarrhoea, malaria, pneumonia, asthma and COPD by Amlodipine, ORS, Norfloxacin, Chloroquine, Azithromycin, salbutamol rotacaps; Appropriate referral
    PhasePhase 4
    Registry statusCompleted

  • Norfloxacin In The Primary Prophylaxis Of Spontaneous Bacterial Peritonitis

    NCT00359853 · start 2000-09

    Registered record
    Registry ID
    NCT00359853
    Conditions
    Spontaneous Bacterial Peritonitis; Hepatorenal Syndrome; Cirrhosis
    Interventions
    Oral norfloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2000-09
    Completion
    2005-03
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSpontaneous Bacterial Peritonitis; Hepatorenal Syndrome; Cirrhosis
    InterventionOral norfloxacin
    PhasePhase 4
    Registry statusCompleted

  • An Observational Study of Oral Fluoroquinolones and the Risk of Retinal Detachment

    NCT01881438 · start 2000-01

    Registered record
    Registry ID
    NCT01881438
    Conditions
    Retinal Detachment
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2000-01
    Completion
    2013-05
    Enrolment
    119,924

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRetinal Detachment
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Liver Transplantation Versus Alternative Therapies for Patients With Pugh B Alcoholic Cirrhosis

    NCT00701792 · start 1994-03

    Registered record
    Registry ID
    NCT00701792
    Conditions
    Cirrhosis
    Interventions
    liver transplantation; standard care for liver disease
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    1994-03
    Completion
    2006-11
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCirrhosis
    Interventionliver transplantation; standard care for liver disease
    PhaseNot applicable
    Registry statusCompleted

  • Vasoactive Peptides in Portal Pressure

    NCT00163982

    Registered record
    Registry ID
    NCT00163982
    Conditions
    Portal Hypertension
    Interventions
    Norfloxacin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPortal Hypertension
    InterventionNorfloxacin
    PhaseNot applicable
    Registry statusUnknown

  • Probiotics for Portal Hypertension

    NCT01134692

    Registered record
    Registry ID
    NCT01134692
    Conditions
    Cirrhosis; Varices, Esophageal
    Interventions
    Propranolol, Norfloxacin, VSL#3
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCirrhosis; Varices, Esophageal
    InterventionPropranolol, Norfloxacin, VSL#3
    PhasePhase 3
    Registry statusUnknown